SABS — SAB Biotherapeutics Income Statement
0.000.00%
Last trade - 00:00- $26.21m
- -$13.49m
- $2.24m
- 29
- 31
- 15
- 15
Annual income statement for SAB Biotherapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 55.2 | 60.9 | 23.9 | 2.24 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 34.7 | 73.6 | 52.8 | 40.3 |
| Operating Profit | 20.6 | -12.7 | -28.9 | -38.1 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | 20.1 | -17.1 | -18.7 | -42.2 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | 20.1 | -17.1 | -18.7 | -42.2 |
| Net Income Before Extraordinary Items | ||||
| Net Income | 20.1 | -17.1 | -18.7 | -42.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | 20.1 | -17.1 | -18.7 | -42.2 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | 7.45 | -4.15 | -4.31 | -7.64 |
| Dividends per Share |